Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10158434 | European Journal of Pharmacology | 2018 | 21 Pages |
Abstract
At early follow up we did not observe events of grade 3 or 4. We observe correlation between events and endothelial dysfunction at baseline and age (OR 1.9, CI 95% 0.05-5.804, P- value: 0.038 for RHI<1.67; OR 1,4, CI 95%0.99-2.56, P- value: 0.04 for age). Our results suggest that therapy with carfilzomib when used as first line therapy is responsible for increase in systemic blood pressure, alteration of endothelium-mediated vascular dilatation and early myocardial diastolic dysfunction.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Mara Gavazzoni, Carlo Mario Lombardi, Enrico Vizzardi, Elio Gorga, Edoardo Sciatti, Laura Rossi, Angelo Belotti, Giuseppe Rossi, Marco Metra, Riccardo Raddino,